The Rights of Children and Parents In Regard to Children Receiving Psychiatric Diagnoses and Drugs. Children & Society, 28, (2014) pp. 231-241 Peter R. Breggin, MD Based on the author’s extensive clinical, forensic and research experience, this article addresses the scientific and moral question of whether it is ever in the best interests of a […]
Breggin, P.R. The New York Times, Oct 13, 2011. The drugging of children for A.D.H.D. has become an epidemic. More than 5 million U.S. children, or 9.5 percent, were diagnosed with A.D.H.D. as of 2007. About 2.8 million had received a prescription for a stimulant medication in 2008. … BregginADHDaMisdiagnosisAnywhere102011NYT.pdf
Chapter from the 2001 book, This is Madness Too, eds. Craig Newnes, Guy Holmes, and Calisie Dunn. whatpeople.pbreggin.2001.pdf
Ethical Human Sciences and Services Vol. 2 No. 2 (2000). Editorial. Prescriptions of Ritalin and of various antidepressants for children as young as two is on the rise, even though the drugs are not FDA approved for use in children, and, indeed, have been shown to have particularly severe adverse reactions in children. thepsychiatric.pbreggin.2000.pdf
On June 28, 2007 more than 250 headlines around the world promised that SSRI antidepressants (such as Prozac, Paxil, Zoloft, and Celexa) are safe for pregnant mothers and their developing babies. “Mom’s Antidepressant Use Poses Little Danger to Baby,” heralded the Atlanta Journal Constitution. “Antidepressants pose low birth defect risk,” claimed Boston Globe. The New York Times ran with the Associated Press’s article titled “Antidepressants Not Big Risk for Defects.” The Wall Street Journal’s coverage was titled “Reassurance on Antidepressants in Pregnancy.” The day before the news stories broke, the Centers for Disease Control spun the news in advance with a press release headlined, “New Study Finds Few Risks of Birth Defects from Antidepressant Use During Pregnancy” (CDC Division of Media, 2007).
Risks and Mechanism of Action of Stimulants. NIH Consensus Development Conference on Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder, November 16-18, 1998. BregginNIHConsensusRisks&MechanismOfActionStim.pdf
Breggin, PR. (1993). Changes, 11(1): 59-71. A look at the dangers inherent in the political use of biological psychiatry, specifically in the so-called ‘violence initiative’. abiomedical.pbreggin.1993.pdf